Applying Pharmacoeconomics in Community and Hospital Pharmacy Research

  • Syed Tabish Razi ZaidiEmail author
  • Zaheer-Ud-Din Babar


Increasing pressure on maximising the output from limited resources has forced health-care policy makers to use health economic evaluation tools to evaluate the efficacy and efficiency of pharmacy services. Increasingly to evaluate these services, pharmacoeconomic evaluation is being used. This chapter introduces the concept of pharmacoeconomics and discusses different pharmacoeconomic methodologies. It also traverses literature covering economic evaluation studies in community and hospital pharmacy setting. The chapter discusses conducting economic evaluations and debates issues related to data sources, perspectives, costs, outcomes measures, sensitivity analysis and strengths, weaknesses and opportunities related to this research.


Economic Evaluation Societal Perspective Community Pharmacy Pharmacy Service Pharmacoeconomic Analysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aspinall SL, Smith KJ, Good CB et al (2013) Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients. Appl Health Econ Health Policy 11(6):653–660CrossRefPubMedGoogle Scholar
  2. Avery AJ, Rodgers S, Cantrill JA et al (2012) A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet 379(9823):1310–1319CrossRefPubMedGoogle Scholar
  3. Branham AR, Katz AJ, Moose JS, Ferreri SP, Farley JF, Marciniak MW (2013) Retrospective analysis of estimated cost avoidance following pharmacist-provided medication therapy management services. J Pharm Pract 26(4):420–427CrossRefPubMedGoogle Scholar
  4. Byford S, Raftery J (1998) Perspectives in economic evaluation. BMJ 316(7143):1529–1530CrossRefPubMedCentralPubMedGoogle Scholar
  5. CDC (2014) Fast stats-health expenditures. Accessed 16 October 2014
  6. Chan AL, Wang HY (2004) Pharmacoeconomic assessment of clinical pharmacist interventions for patients with moderate to severe asthma in outpatient clinics: experience in Taiwan. Clin Drug Investig 24(10):603–609CrossRefPubMedGoogle Scholar
  7. Chisholm MA, Vollenweider LJ, Mulloy LL, Wynn JJ, Wade WE, DiPiro JT (2000) Cost-benefit analysis of a clinical pharmacist-managed medication assistance program in a renal transplant clinic. Clin Transplant 14(4 Pt 1):304–307CrossRefPubMedGoogle Scholar
  8. Chuang LC, Sutton JD, Henderson GT (1994) Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit. Hosp Pharm 29(3):215–218, 221PubMedGoogle Scholar
  9. Cies JJ, Varlotta L (2013) Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients. Pediatr Pulmonol 48(12):1190–1194CrossRefPubMedGoogle Scholar
  10. Committee PBA (2014) Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Accessed 16 October 2014
  11. Cooper JW Jr (1997) Consultant pharmacist drug therapy recommendations from monthly drug regimen reviews in a geriatric nursing facility: a two-year study and cost analysis. J Nutr Health Aging 1(3):181–184PubMedGoogle Scholar
  12. Cowper PA, Weinberger M, Hanlon JT et al (1998) The cost-effectiveness of a clinical pharmacist intervention among elderly outpatients. Pharmacotherapy 18(2):327–332PubMedGoogle Scholar
  13. Crowson K, Collette D, Dang M, Rittase N (2002) Transformation of a pharmacy department: impact on pharmacist interventions, error prevention, and cost. Jt Comm J Qual Improv 28(6):324–330PubMedGoogle Scholar
  14. Desborough JA, Sach T, Bhattacharya D, Holland RC, Wright DJ (2012) A cost-consequences analysis of an adherence focused pharmacist-led medication review service. Int J Pharm Pract 20(1):41–49CrossRefPubMedGoogle Scholar
  15. Devlin JW, Holbrook AM, Fuller HD (1997) The effect of ICU sedation guidelines and pharmacist interventions on clinical outcomes and drug cost. Ann Pharmacother 31(6):689–695PubMedGoogle Scholar
  16. Dranitsaris G, Warr D, Puodziunas A (1995) A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 3(3):183–189CrossRefPubMedGoogle Scholar
  17. Drummond MFSM, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, OxfordGoogle Scholar
  18. Elliott RA, Putman K, Davies J, Annemans L (2014) A review of the methodological challenges in assessing the cost effectiveness of pharmacist Interventions. Pharmacoeconomics 32(12):1185–1199CrossRefPubMedGoogle Scholar
  19. Gray DR, Garabedian-Ruffalo SM, Chretien SD (2007) Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Ann Pharmacother 41(3):496–501CrossRefPubMedGoogle Scholar
  20. Grindrod K, Sanghera N, Rahmaan I, Roy M, Tritt M (2013) Living MedsCheck: Learning how to deliver MedsCheck in community practice in Ontario. Can Pharm J (Ott) 146(1):33–38CrossRefGoogle Scholar
  21. Gyllensten H, Hakkarainen KM, Hagg S et al (2014) Economic impact of adverse drug events–a retrospective population-based cohort study of 4970 adults. PLoS One 9(3):e92061CrossRefPubMedCentralPubMedGoogle Scholar
  22. Hilleman DE, Faulkner MA, Monaghan MS (2004) Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia. Pharmacotherapy 24(8):1077–1083CrossRefPubMedGoogle Scholar
  23. Husereau D, Drummond M, Petrou S et al (2013a) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 346:f1049CrossRefPubMedGoogle Scholar
  24. Husereau D, Drummond M, Petrou S et al (2013b) Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16(2):231–250CrossRefPubMedGoogle Scholar
  25. Jackson T (2000) Cost estimates for hospital inpatient care in Australia: evaluation of alternative sources. Aust N Z J Public Health 24(3):234–241CrossRefPubMedGoogle Scholar
  26. Johnson SG (2009) Improving cost-effectiveness of and outcomes from drug therapy in patients with atrial fibrillation in managed care: role of the pharmacist. J Manag Care Pharm 15(6 Suppl B):S19–25PubMedGoogle Scholar
  27. Kane-Gill SL, Jacobi J, Rothschild JM (2010) Adverse drug events in intensive care units: risk factors, impact, and the role of team care. Crit Care Med 38(6 Suppl):S83–89CrossRefPubMedGoogle Scholar
  28. Klepser DG, Bisanz SE, Klepser ME (2012) Cost-effectiveness of pharmacist-provided treatment of adult pharyngitis. Am J Manag Care 18(4):e145–154PubMedGoogle Scholar
  29. Kopp BJ, Mrsan M, Erstad BL, Duby JJ (2007) Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm 64(23):2483–2487CrossRefPubMedGoogle Scholar
  30. Locatelli I, Marazzi A (2013) Robust parametric indirect estimates of the expected cost of a hospital stay with covariates and censored data. Stat Med 32(14):2457–2466CrossRefPubMedGoogle Scholar
  31. Lucca JM, Ramesh M, Narahari GM, Minaz N (2012) Impact of clinical pharmacist interventions on the cost of drug therapy in intensive care units of a tertiary care teaching hospital. J Pharmacol Pharmacother 3(3):242–247CrossRefPubMedCentralPubMedGoogle Scholar
  32. Marciante KD, Gardner JS, Veenstra DL, Sullivan SD (2001) Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. Am J Public Health 91(9):1443–1445CrossRefPubMedCentralPubMedGoogle Scholar
  33. Martinez AS, Saef J, Paszczuk A, Bhatt-Chugani H (2013) Implementation of a pharmacist-managed heart failure medication titration clinic. Am J Health Syst Pharm 70(12):1070–1076CrossRefPubMedGoogle Scholar
  34. Mason JM, Mason AR (2006) The generalisability of pharmacoeconomic studies: issues and challenges ahead. Pharmacoeconomics 24(10):937–945CrossRefPubMedGoogle Scholar
  35. McBride P, Stone NJ, Blum CB (2014) Should family physicians follow the new ACC/AHA cholesterol treatment guideline? Yes: implementing the new ACC/AHA cholesterol guideline will improve cardiovascular Outcomes. Am Fam Physician 90(4):212–216PubMedGoogle Scholar
  36. Mutchie KD, Smith KA, MacKay MW, Marsh C, Juluson D (1979) Pharmacist monitoring of parenteral nutrition: clinical and cost effectiveness. Am J Hosp Pharm 36(6):785–787PubMedGoogle Scholar
  37. Ottenbros S, Teichert M, de Groot R et al (2014) Pharmacist-led intervention study to improve drug therapy in asthma and COPD patients. Int J Clin Pharm 36(2):336–344CrossRefPubMedGoogle Scholar
  38. Perraudin C, Le Vaillant M, Pelletier-Fleury N (2013) Cost-Effectiveness of a Community Pharmacist-Led Sleep Apnea Screening Program - A Markov Model. PLoS One 8(6):e63894CrossRefPubMedCentralPubMedGoogle Scholar
  39. Rawlins M, Barnett D, Stevens A (2010) Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 70(3):346–349CrossRefPubMedCentralPubMedGoogle Scholar
  40. Rubio-Valera M, Bosmans J, Fernandez A et al (2013) Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study). PLoS One 8(8):e70588CrossRefPubMedCentralPubMedGoogle Scholar
  41. Sanchez LA, Lee JT (2000) Applied pharmacoeconomics: modeling data from internal and external sources. Am J Health Syst Pharm 57(2):146–155, quiz 155-146PubMedGoogle Scholar
  42. Saokaew S, Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A, Jeanpeerapong N (2013) Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand. Thromb Res 132(4):437–443CrossRefPubMedGoogle Scholar
  43. Sorensen L, Stokes JA, Purdie DM, Woodward M, Elliott R, Roberts MS (2004) Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol 58(6):648–664CrossRefPubMedCentralPubMedGoogle Scholar
  44. Tan Torres Edejer T, Baltussen R, Adam T et al (2003) Making Choices in Health: WHO guide to cost-effectiveness analysis. World Health Organisation, GenevaGoogle Scholar
  45. Thavorn K, Chaiyakunapruk N (2008) A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control 17(3):177–182CrossRefPubMedGoogle Scholar
  46. van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ, Vegter S (2014) Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. J Manag Care Pharm 20(8):786–792PubMedGoogle Scholar
  47. Wallerstedt SM, Bladh L, Ramsberg J (2012) A cost-effectiveness analysis of an in-hospital clinical pharmacist service. BMJ Open 2:e000329CrossRefPubMedCentralPubMedGoogle Scholar
  48. Weant KA, Armitstead JA, Ladha AM, Sasaki-Adams D, Hadar EJ, Ewend MG (2009) Cost effectiveness of a clinical pharmacist on a neurosurgical team. Neurosurgery 65(5):946–950, discussion 950-941CrossRefPubMedGoogle Scholar
  49. Zaidi ST, Hassan Y, Postma MJ, Ng SH (2003) Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital. Pharm World Sci 25(6):299–302CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Pharmacy, School of MedicineUniversity of TasmaniaHobartAustralia
  2. 2.Faculty of Medical and Health Sciences, School of PharmacyUniversity of AucklandAucklandNew Zealand

Personalised recommendations